Closed Pfizer biopharma facility in Everett gets a new owner and a mystery tenant
Breakthrough Properties said it bought Seagen’s 270,000 sq ft Everett, Wash. bio-manufacturing campus for $78 million and leased it for 21 years to an unnamed global biopharmaceutical company. Seagen spent about $350 million building it, but Pfizer, after acquiring Seagen for $43 billion in 2023, wound down construction. Breakthrough’s JV with Tishman Speyer and Bellco Capital declined tenant details.
How this was made
The 30-second read
Why it matters
Breakthrough Properties acquired the facility for $78M and leased the entire campus for 21 years to an unnamed global biopharmaceutical company, implying renewed manufacturing capacity utilization in the region.
Market read
A $78M life-sciences real-estate acquisition with a long lease supports the narrative of expanding US biomanufacturing capacity, but the unnamed tenant prevents direct single-stock trading signals.
What to watch
The key trading variable is whether the new tenant actually restarts manufacturing and ramps utilization; without move-in date and product scope, near-term financial implications are unclear.
Background
The Everett facility was built by Seagen for drug manufacturing but was never opened after Pfizer acquired Seagen in 2023.
Market effects
Signals continued pharma manufacturing capacity buildout and life-sciences real estate demand, but tenant opacity limits company-specific read-through.
Highlights Puget Sound life-sciences investment and reuse of a Pfizer-era Seagen buildout in Everett.
Moderate, reflects broader US onshoring and supply-chain resilience themes rather than a global policy shift.
Counterpoint
Because the tenant is unnamed and no manufacturing contract terms are disclosed, the deal may have limited impact on any specific public pharma stock.
Key entities
- companyBreakthrough Properties
Life-sciences real estate company that acquired the Everett facility for $78M and secured a 21-year lease to an unnamed biopharma tenant.
- companySeagen
Built the 270,000-square-foot Everett facility with about $350M investment, but never moved in under Pfizer ownership.
- companyPfizer
Acquired Seagen in 2023 and later wound down construction of the Everett site after evaluating manufacturing network capacity.
